+1 877 705 191424 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 75Years
All Genders
ID06205992

Comparing Three-Dimensional and Two-Dimensional MR Elastography to Assess Cirrhosis and Portal Hypertension in Adults

Led by Shengjing Hospital · Updated on 2026-02-09

100

Participants Needed

1

Research Sites

17 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating new non-invasive methods to predict hepatic venous pressure gradient HVPG, a key measure in managing portal hypertension in cirrhosis. This study compares three-dimensional magnetic resonance elastography 3D-MRE with two-dimensional magnetic resonance elastography 2D-MRE to develop a risk stratification system that can guide personalized treatment for portal hypertension. Cirrhosis and portal hypertension pose significant health challenges, making less invasive diagnostic tools important for patient care. Participants will undergo imaging using either 3D-MRE or 2D-MRE, both performed on a 3.0-T MRI system with an eight-channel body coil. The study features two groups one developing a model using 3D-MRE and a control group using 2D-MRE. Hepatic venous pressure gradient measurements are taken by trained radiologists following standard procedures. Comparing these imaging techniques aims to evaluate their accuracy in assessing portal hypertension. During the study, participants will have imaging and HVPG measurements within one month to ensure data consistency. Researchers will assess the accuracy of 3D-MRE and 2D-MRE features for predicting portal hypertension over a 12-month period. The study monitors participants through these diagnostic tests and evaluates how well the imaging models can predict HVPG, contributing to safer, more convenient management of cirrhosis-related complications.

CONDITIONS

Brief Title

3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age over 18 years
  • Confirmed cirrhosis by laboratory tests, imaging, and clinical symptoms
  • Underwent 3D-MRE and 2D-MRE imaging within 1 month prior to HVPG measurement
  • Provided written informed consent
Not Eligible

You will not qualify if you...

  • Previous liver or spleen surgery
  • Liver cancer or chronic acute liver failure
  • Acute portal hypertension
  • Unreliable HVPG, 3D-MRE, or 2D-MRE results due to technical reasons
  • Received liver interventional therapy between HVPG and MRE imaging

Research Team

Y

Yu Shi

Z

Zhiying Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here